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We have previously reported that the Parkinson’s disease-
associated kinase PINK1 (PTEN-induced putative kinase 1)
is activated by mitochondrial depolarization and stimulates
the Parkin E3 ligase by phosphorylating Ser65 within its Ubl
(ubiquitin-like) domain. Using phosphoproteomic analysis, we
identified a novel ubiquitin phosphopeptide phosphorylated at
Ser65 that was enriched 14-fold in HEK (human embryonic
kidney)-293 cells overexpressing wild-type PINK1 stimulated
with the mitochondrial uncoupling agent CCCP (carbonyl
cyanide m-chlorophenylhydrazone), to activate PINK1, compared
with cells expressing kinase-inactive PINK1. Ser65 in ubiquitin
lies in a similar motif to Ser65 in the Ubl domain
of Parkin. Remarkably, PINK1 directly phosphorylates Ser65 of
ubiquitin in vitro. We undertook a series of experiments that
provide striking evidence that Ser65-phosphorylated ubiquitin
(ubiquitinPhospho−Ser65) functions as a critical activator of Parkin.
First, we demonstrate that a fragment of Parkin lacking the
Ubl domain encompassing Ser65 (Ubl-Parkin) is robustly
activated by ubiquitinPhospho−Ser65, but not by non-phosphorylated
ubiquitin. Secondly, we find that the isolated Parkin Ubl domain
phosphorylated at Ser65 (UblPhospho−Ser65) can also activate Ubl-
Parkin similarly to ubiquitinPhospho−Ser65. Thirdly, we establish
that ubiquitinPhospho−Ser65, but not non-phosphorylated ubiquitin or
UblPhospho−Ser65, activates full-length wild-type Parkin as well as the
non-phosphorylatable S65A Parkin mutant. Fourthly, we provide
evidence that optimal activation of full-length Parkin E3 ligase is
dependent on PINK1-mediated phosphorylation of both Parkin at
Ser65 and ubiquitin at Ser65, since only mutation of both proteins
at Ser65 completely abolishes Parkin activation. In conclusion, the
findings of the present study reveal that PINK1 controls Parkin
E3 ligase activity not only by phosphorylating Parkin at Ser65,
but also by phosphorylating ubiquitin at Ser65. We propose that
phosphorylation of Parkin at Ser65 serves to prime the E3 ligase
enzyme for activation by ubiquitinPhospho−Ser65, suggesting that small
molecules that mimic ubiquitinPhospho−Ser65 could hold promise as
novel therapies for Parkinson’s disease.
Key words: Parkin, Parkinson’s disease, phosphorylation, PTEN
(phosphatase and tensin homologue deleted on chromosome
10)-induced putative kinase 1 (PINK1), ubiquitin.
INTRODUCTION
Mutations in PINK1 [PTEN (phosphatase and tensin homologue
deleted on chromosome 10)-induced putative kinase 1] and
Parkin are associated with early-onset autosomal-recessive PD
(Parkinson’s disease) [1,2]. Several lines of evidence indicate
that these enzymes function in a common signalling pathway.
For example, patients bearing PINK1 or Parkin mutations share
a similar phenotype [3–5], and compelling genetic studies in
Drosophila melanogaster suggests that PINK1 acts upstream
of Parkin [6–8]. Furthermore, PINK1 has been reported to
be required for Parkin recruitment to mitochondria upon
mitochondrial membrane depolarization in mammalian cell lines
[9–12]. We recently found that PINK1 can phosphorylate Parkin
directly at a highly conserved residue, Ser65, that lies within
the Ubl (ubiquitin-like) domain of Parkin and demonstrated
that phosphorylation stimulates Parkin E3 ligase activity [13].
Recent high-resolution crystal structures of Parkin lacking the
Ubl domain suggest that Parkin is autoinhibited; however,
the studies do not shed any light on the mechanism of how Ser65
phosphorylation triggers conformational change and activation of
Parkin [14–16].
PINK1 is unique among all protein kinases since it possesses a
N-terminal targeting motif that localizes it to the mitochondria
where it undergoes sequential cleavage by mitochondrial
processing protease and the rhomboid protease PARL (presenilin-
associated rhomboid-like protein, mitochondrial) followed by
rapid degradation by the N-end rule pathway [17]. In response
to mitochondrial membrane depolarization, PINK1 becomes
stabilized at the mitochondria where it becomes activated and
autophosphorylates at Thr257 and phosphorylates Parkin at Ser65
[13]. Protein kinases are able to phosphorylate anywhere from
one to a large number of substrates [18]; however, it is unknown
whether PINK1 can phosphorylate additional substrates in the
mitochondria upon mitochondrial depolarization.
In the present study we have identified a novel ubiquitin
phosphopeptide phosphorylated at Ser65 that was enriched
significantly in HEK (human embryonic kidney)-293 cells
Abbreviations: CCCP, carbonyl cyanide m-chlorophenylhydrazone; CDK2, cyclin-dependent kinase 2; GSK3β, glycogen synthase kinase-3β; HEK,
human embryonic kidney; HOIL1, haem-oxidized IRP2 (iron-regulatory protein 2) ubiquitin ligase 1; HRP, horseradish peroxidase; IKK, IκB (inhibitor
of nuclear factor κB) kinase; ISG15, interferon-induced 17 kDa protein; MBP, maltose-binding protein; MLK1, mixed lineage kinase 1; Nedd8, neural-
precursor-cell-expressed developmentally down-regulated 8; Ni-NTA, Ni2 + -nitrilotriacetate; NUAK1, NUAK family SNF1-like kinase 1; OTU1, OTU (ovarian
tumour) domain-containing protein 1; PD, Parkinson’s disease; PINK1, PTEN (phosphatase and tensin homologue deleted on chromosome 10)-induced
putative kinase 1; PLK1, Polo-like kinase 1; SILAC, stable isotope labelling by amino acids in cell culture; SUMO, small ubiquitin-related modifier; TCEP,
tris-(2-carboxyethyl)phosphine; TcPINK1, Tribolium castaneum PINK1; Ubl, ubiquitin-like.
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expressing wild-type PINK1 upon PINK1 activation by
the mitochondrial uncoupler CCCP (carbonyl cyanide m-
chlorophenylhydrazone), compared with cells expressing kinase-
inactive PINK1. We demonstrate that PINK1 can directly
phosphorylate ubiquitin specifically at Ser65. Using a Ubl-deleted
fragment of Parkin, Ubl-Parkin (which lacks the Parkin Ser65
site), we observe robust enhancement in Parkin E3 ligase activity
upon phosphorylation by wild-type, but not kinase-inactive,
PINK1 and this effect on activity is abolished if we use an
S65A ubiquitin mutant in our assays. To obtain definitive insights
into the role of PINK1-induced phosphorylation of ubiquitin in
regulating Parkin activity, we have purified Ser65-phosphorylated
ubiquitin (ubiquitinPhospho−Ser65) to homogeneity and demonstrate
that in stark contrast with non-phosphorylated ubiquitin, it is
capable of activating both full-length wild-type and Ubl-Parkin
E3 ligase activity. The present study provides fundamental novel
mechanistic insights into how PINK1 activates Parkin E3 ligase
activity and suggests a dual regulatory mechanism of Parkin
E3 ligase activity in which PINK1-dependent phosphorylation
of Parkin at Ser65 is required to prime Parkin for activation by
ubiquitinPhospho−Ser65.
MATERIALS AND METHODS
Materials
[γ -32P]ATP was from PerkinElmer. All mutagenesis was
carried out using the QuikChange® site-directed mutagenesis
method (Stratagene) with KOD polymerase (Novagen). All
DNA constructs were verified by DNA sequencing, which
was performed by the Sequencing Service, College of Life
Sciences, University of Dundee, Dundee, Scotland, U.K., using
DYEnamic ET terminator chemistry (GE Healthcare) on Applied
Biosystems automated DNA sequencers. DNA for bacterial
protein expression was transformed into Escherichia coli BL21-
CodonPlus (DE3)-RIL cells (Stratagene). All cDNA plasmids,
antibodies and recombinant proteins generated for the present
study are available on request through our reagents website
(https://mrcppureagents.dundee.ac.uk/).
Antibodies
An antigen affinity-purified sheep anti-SUMO-1 (small ubiquitin-
related modifier 1) antibody was a gift from Professor Ron
Hay (College of Life Sciences, University of Dundee, Dundee,
Scotland, U.K.). An anti-Parkin mouse monoclonal antibody was
obtained from Santa Cruz Biotechnology. An HRP (horseradish
peroxidase)-conjugated anti-FLAG antibody was obtained from
Sigma.
Immunoblotting
Samples were subjected to SDS/PAGE (4–12% gels) and
were transferred on to nitrocellulose membranes. Membranes
were blocked for 1 h in TBST [Tris-buffered saline
(50 mM Tris/HCl and 150 mM NaCl, pH 7.5) with 0.1%
Tween 20] containing 5% (w/v) non-fat dried skimmed
milk powder. Membranes were probed with the indicated
antibodies in TBST containing 5% (w/v) non-fat dried skimmed
milk powder overnight at 4 ◦C. Detection was performed
using HRP-conjugated secondary antibodies and enhanced
chemiluminescence reagent.
Cell culture
Flp-In T-Rex stable cell lines were cultured using DMEM
(Dulbecco’s modified Eagle’s medium) supplemented with 10%
FBS, 2 mM L-glutamine, 1×penicillin/streptomycin, 15 μg/ml
blasticidin and 100 μg/ml hygromycin. Cultures were induced
to express protein by the addition of 0.1 μg/ml doxycycline in the
medium for 24 h. To uncouple mitochondria, cells were treated
with 10 μM CCCP (Sigma) dissolved in DMSO for 3 h.
Identification of Ser65 phosphorylation of ubiquitin by MS
We undertook a SILAC (stable isotope labelling by amino acids
in cell culture)-based quantitative phosphoproteomic screen in
Flp-In T-Rex HEK-293 cells stably expressing FLAG-empty (L),
wild-type (H) or kinase-inactive (M) PINK1–FLAG. Cells were
stimulated with 10 μM CCCP for 3 h and homogenized in 8.55%
(w/v) sucrose and 3 mM imidazole (pH 7.4) (supplemented with
protease and phosphatase inhibitor cocktail from Roche, and
benzonase from Roche). Mitochondria-containing membrane
fractions were enriched by ultracentrifugation and solubilized in
1% RapiGestTM (Waters). Lysates were mixed from each cell
condition at 1:1:1 before being subjected to tryptic digestion.
Digested peptides were subjected to TiO2 phosphopeptide
enrichment [19,20] and analysed by LC–MS on an Orbitrap Velos
Pro (Thermo Fisher). Data were analysed using Maxquant 1.3.0.5
[21] and Xcalibur software (Thermo Fisher). More details and the
full analysis of the screen are available on request (C. Kondapalli,
B. Dill, J. Proctor, A. Kazlauskaite, M. Trost and M. Muqit,
unpublished work).
In vitro ubiquitylation assays
Wild-type or Ubl-Parkin (residues 80–465) (2 μg) was initially
incubated with 1 μg of E. coli-expressed wild-type or kinase-
inactive (D359A) MBP (maltose-binding protein)–TcPINK1
(Tribolium castaneum PINK1) in a reaction volume of 25 μl
[50 mM Tris/HCl (pH 7.5), 0.1 mM EGTA, 10 mM magnesium
acetate, 1% 2-mercaptoethanol and 0.1 mM ATP]. Kinase assays
were carried out at 30 ◦C for 60 min followed by addition
of ubiquitylation assay components and Mastermix to a final
volume of 50 μl [50 mM Tris/HCl (pH 7.5), 0.05 mM EGTA,
10 mM MgCl2, 0.5% 2-mercaptoethanol, 0.12 μM human
recombinant E1 purified from the Sf21 insect cell line, 1 μM
human recombinant UbcH7 and 2 μg of His6–SUMO-Miro1
both purified from E. coli, 0.05 mM FLAG–ubiquitin (Boston
Biochem) and 2 mM ATP]. Ubiquitylation reactions were carried
out at 30 ◦C for 60 min and terminated by the addition of
SDS sample buffer. For all assays, reaction mixtures were
resolved by SDS/PAGE (4–12% gel). Ubiquitylation reaction
products were subjected to immunoblotting with an anti-FLAG
antibody (Sigma, 1:10000), or anti-Parkin or anti-SUMO1
antibodies.
Experiments investigating the effect of ubiquitinPhospho−Ser65 and
UblPhospho−Ser65 (isolated Parkin Ubl domain phosphorylated at
Ser65) on Parkin activity, ubiquitylation reactions were performed
in the absence of PINK1 in a final volume of 50 μl [50 mM
Tris/HCl (pH 7.5), 5 mM MgCl2, 0.12 μM ubiquitin E1, 1 μM
UbcH7, 2 μg of His6–SUMO-Miro1 and 2 mM ATP]. When the
effects of ubiquitinPhospho−Ser65 were investigated, the total amount
of ubiquitin used per assay was 25 μg; increasing concentrations
of ubiquitinPhospho−Ser65 or non-phosphorylated ubiquitin were
added as indicated and the final amount of ubiquitin was
reached by the addition of FLAG–ubiquitin. When the effects of
UblPhospho−Ser65 were investigated, 0.05 mM FLAG–ubiquitin was
used and the UblPhospho−Ser65 or non-phosphorylated-Ubl were added
c© 2014 The Author(s) The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Licence (CC-BY) (http://creativecommons.org/licenses/by/3.0/) which
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as indicated. Ubiquitylation reactions were carried out at 30 ◦C
for 60 min, terminated by the addition of SDS sample buffer and
subjected to immunoblotting as described above.
In vitro E2-discharge assays
Wild-type or indicated mutants of Parkin (2 μg) were incubated
with 1 μg of E. coli-expressed wild-type or kinase-inactive
(D359A) MBP–TcPINK1 in a reaction volume of 15 μl [50 mM
Hepes (pH 7.5), 10 mM magnesium acetate and 0.1 mM ATP].
Kinase assays were carried out at 30 ◦C for 60 min. The E2-
charging reaction was assembled in parallel in a 5 μl volume
containing Ube1 (0.5 μg), UbcH7 (2 μg), 50 mM Hepes (pH 7.5)
and 10 μM ubiquitin in the presence of 2 mM magnesium acetate
and 0.2 mM ATP. After an initial incubation of 60 min at 30 ◦C,
the reactions were combined and allowed to continue for a further
15 min at 30 ◦C. Reactions were terminated by the addition of 5 μl
of SDS sample loading buffer and were subjected to SDS/PAGE
(4–12% gel) analysis in the absence of any reducing agent. Gels
were stained using InstantBlue.
During experiments investigating the effect of
ubiquitinPhospho−Ser65 and UblPhospho−Ser65 on the Parkin-mediated E2
discharge, 1 μg of the indicated ubiquitin and Ubl species were
combined with the E2-discharge reaction.
Kinase assays
Reactions were set up in a volume of 25 μl, using 2 μg of wild-
type or S65A ubiquitin mutants of Parkin and 1 μg of E. coli-
expressed wild-type or kinase-inactive (D359A) MBP–TcPINK1,
in 50 mM Tris/HCl (pH 7.5), 0.1 mM EGTA, 10 mM MgCl2,
2 mM DTT and 0.1 mM [γ -32P]ATP. Assays were incubated
at 30 ◦C with shaking at 1050 rev./min and terminated after
60 min by the addition of SDS sample loading buffer. The
reaction mixtures were then resolved by SDS/PAGE (4–12%
gel). Proteins were detected by Coomassie Blue staining and gels
were imaged using an Epson scanner and dried completely using
a gel dryer (Bio-Rad Laboratories). Incorporation of [γ -32P]ATP
into substrates was analysed by autoradiography using Amersham
Hyperfilm.
Buffers for E. coli protein purification
For Parkin purification, the following buffers were used. Lysis
buffer contained 50 mM Tris/HCl (pH 7.5), 150 mM NaCl,
1 mM EDTA, 1 mM EGTA, 5% (v/v) glycerol, 1% (v/v)
Triton X-100, 0.1% 2-mercaptoethanol, 1 mM benzamidine and
0.1 mM PMSF. Wash buffer contained 50 mM Tris/HCl (pH 7.5),
500 mM NaCl, 0.1 mM EGTA, 5% (v/v) glycerol, 0.03% Brij-
35, 0.1% 2-mercaptoethanol, 1 mM benzamidine and 0.1 mM
PMSF. Equilibration buffer contained 50 mM Tris/HCl (pH 7.5),
150 mM NaCl, 0.1 mM EGTA, 5% (v/v) glycerol, 0.03% Brij-
35, 0.1% 2-mercaptoethanol, 1 mM benzamidine and 0.1 mM
PMSF. Elution buffer was equilibration buffer with the addition of
12 mM maltose. Storage buffer was equilibration buffer with the
addition of 0.27 M sucrose and glycerol, PMSF and benzamidine
were omitted.
Protein purification from E. coli
Full-length wild-type or kinase-inactive TcPINK1 was expressed
in E. coli as an MBP-fusion protein and purified as described
previously [22]. Briefly, transformed BL21-CodonPlus (DE3)-
RIL cells were grown at 37 ◦C to a D600 of 0.3, then shifted to
16 ◦C and induced with 250 μM IPTG at a D600 of 0.5. Cells were
induced with 250 μM IPTG at a D600 of 0.6 and were further grown
at 16 ◦C for 16 h. Cells were pelleted at 3300 g (4 ◦C for 10 min),
and then lysed by sonication (45% amplitude, 10 s on/10 s off;
1 min 40 s total sonication time) in lysis buffer. Lysates were
clarified by centrifugation at 30000 g for 30 min at 4 ◦C followed
by incubation with 1 ml of amylose resin/litre of culture for 1.5 h
at 4 ◦C. The resin was washed thoroughly in wash buffer followed
by equilibration buffer, and proteins were then eluted. Proteins
were dialysed overnight at 4 ◦C into storage buffer, snap-frozen
and stored at − 80 ◦C until use.
Wild-type and indicated mutant untagged Parkin (His6–SUMO-
cleaved) was expressed and purified using a modified protocol
[23]. BL21-CodonPlus (DE3)-RIL cells were transformed with
His6–SUMO-tagged Parkin constructs, and overnight cultures
were prepared and used to inoculate 12× 1 litre volumes of LB
medium (containing 50 μg/ml carbenicillin and 0.25 mM ZnCl2).
The cells were grown at 37 ◦C until the D600 was 0.4 and the
temperature was lowered to 16 ◦C. At a D600 of 0.8 expression was
induced with 25 μM IPTG. After overnight incubation the cells
were collected and lysed in 75 mM Tris/HCl (pH 7.5), 500 mM
NaCl, 0.2% Triton X-100, 25 mM imidazole, 0.5 mM TCEP
[tris-(2-carboxyethyl)phosphine], 1 mM Pefabloc and 10 μg/ml
leupeptin. After sonication (45% amplitude, 10 s on/10 s off;
1 min 40 s total sonication time) and removal of insoluble
material, His6–SUMO–Parkin was purified using Ni-NTA (Ni2 + -
nitrilotriacetate)–Sepharose chromatography. The protein was
collected by elution with 400 mM imidazole in 50 mM Tris/HCl
(pH 8.2), 200 mM NaCl, 10% glycerol, 0.03% Brij-35 and
0.5 mM TCEP. This was dialysed twice against 50 mM Tris/HCl
(pH 8.2), 200 mM NaCl, 10% glycerol and 0.5 mM TCEP in
the presence of His6–SENP1-(415–643) at a ratio of 1 mg of
His6–SENP1 per 5 mg of His6–SUMO–Parkin. The protease, the
His6–SUMO tag and any uncleaved protein were removed by two
subsequent incubations with Ni-NTA–Sepharose. The cleaved
Parkin was further purified in 50 mM Tris/HCl (pH 8.2), 200 mM
NaCl, 20% glycerol, 0.03% Brij-35 and 0.5 mM TCEP over a
Superdex 200 column.
Wild-type His6–SUMO-Miro1-(1–592) was expressed in E.
coli. Briefly, BL21-CodonPlus (DE3)-RIL transformed cells were
grown at 37 ◦C to a D600 of 0.4, then shifted to 15 ◦C and
induced with 10 μM IPTG at a D600 of 0.6. Cells were then
grown at 15 ◦C for a further 20 h. Cells were pelleted at 4200 g
and then lysed by sonication (45% amplitude, 10 s on/10 s
off; 1 min 40 s total sonication time) in lysis buffer. Lysates
were clarified by centrifugation at 30000 g for 30 min at 4 ◦C
followed by incubation with cobalt resin at 4 ◦C for 45 min. The
resin was washed thoroughly in high-salt buffer, equilibrated
in low-salt buffer, and the proteins were then eluted. The
eluted Miro1 proteins were further purified by anion-exchange
chromatography. Proteins were applied to a Mono-Q HR 5/5
column and chromatographed with a linear gradient of NaCl
from 0 to 0.5 M. Fractions containing the purified Miro1 protein
were then dialysed, snap-frozen in liquid nitrogen and stored at
− 70 ◦C.
GST-fusion proteins were purified by similar methods in E.
coli except that GST–MLK1 (mixed lineage kinase 1)-(132–413),
GST–OTU1 [OTU (ovarian tumour) domain-containing protein
1], GST–ISG15 (interferon-induced 17 kDa protein) and GST–
CDK2 (cyclin-dependent kinase 2)-(2–298)/cyclin A2-(171–432)
were affinity-purified using GSH–Sepharose chromatography and
for GST–CDK2 and GST–ISG15, the GST tag was cleaved with
PreScission protease. His6–Aurora A-(2–403), His6–SUMO1 and
His6–HOIL1 [haem-oxidized IRP2 (iron-regulatory protein 2)
ubiquitin ligase 1] were purified by similar methods in E. coli
except that recombinant His6-fusion protein was affinity-purified
on Ni-NTA–agarose. Ubiquilin2 was purified by similar methods
c© 2014 The Author(s) The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Licence (CC-BY) (http://creativecommons.org/licenses/by/3.0/) which
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to that for the His6–SUMO fusion protein and then underwent
His6–SUMO tag cleavage. Untagged Nedd8 (neural-precursor-
cell-expressed developmentally down-regulated 8) was expressed
as described previously [24]. His6–IKKε [IκB (inhibitor of
nuclear factor κB) kinase ε]-(1–716), His6–IKKβ-(1–716),
His6–PLK1 (Polo-like kinase 1)-(1–603), His6–NUAK1 (NUAK
family SNF1-like kinase 1)-(2–660) and His6–GSK3β (glycogen
synthase kinase-3β)-(2–420) were purified in a baculovirus
expression vector system using Ni-NTA–agarose as described
previously [25].
Mapping the site on ubiquitin phosphorylated by TcPINK1
FLAG–ubiquitin (10 μg) was incubated with 10 μg of either
wild-type MBP–TcPINK1 (residues 1–570) or kinase-inactive
MBP–TcPINK1 (D359A) for 80 min at 30◦C in 50 mM Tris/HCl
(pH 7.5), 0.1 mM EGTA, 10 mM MgCl2, 0.15 2-mercaptoethanol
and 0.1 mM [γ -32P]ATP (approximately 20000 c.p.m./pmol) in
a total reaction volume of 50 μl. The reaction was terminated
by the addition of SDS sample buffer with 10 mM DTT,
boiled and subsequently alkylated with 50 mM iodoacetamide
before samples were subjected to electrophoresis on a Bis-
Tris 4–12% polyacrylamide gel, which was then stained with
Colloidal Coomassie Blue (Invitrogen). Phosphorylated ubiquitin
was digested with trypsin and 78% of the 32P radioactivity
incorporated into ubiquitin was recovered from the gel bands.
Peptides were chromatographed on a reverse-phase HPLC Vydac
C18 column (catalogue number 218TP5215, Separations Group)
equilibrated in 0.1% trifluoroacetic acid, and the column
developed with a linear acetonitrile gradient at a flow rate of
0.2 ml/min before fractions (0.1 ml each) were collected and
analysed for 32P radioactivity by Cerenkov counting. Isolated
phosphopeptides were analysed by LC–MS/MS on a Thermo
U3000 RSLC nano-LC system coupled to a Thermo LTQ-Orbitrap
Velos mass spectrometer. The resultant data files were searched
using Mascot (http://www.matrixscience.com) run on an in-house
system against a database containing the ubiquitin sequence, with
a 10 p.p.m. mass accuracy for precursor ions, a 0.6 Da tolerance
for fragment ions, and allowing for Phospho (ST), Phospho (Y),
Oxidation (M) and Dioxidation (M) as variable modifications.
Individual MS/MS spectra were inspected using Xcalibur v2.2
software (Thermo Scientific). The site of phosphorylation of
these 32P-labelled peptides was determined by solid-phase Edman
degradation on a Shimadzu PPSQ33A sequencer of the peptide
coupled to Sequelon-AA membrane (Applied Biosystems) as
described previously [26].
Purification of Ser65-phosphorylated ubiquitin and
Ser65-phosphorylated Parkin Ubl domain (residues 1–76)
Bovine ubiquitin (23 μM; Sigma) was phosphorylated for 24 h
with 3.7 μM MBP–TcPINK1 at 22 ◦C in the presence of 100 μM
ATP and 10 mM MgCl2. To replace ADP with ATP, the reaction
was dialysed against Mg2+-ATP solution. Ubiquitin was filtered
through a 30 kDa Vivaspin filter to remove MBP–TcPINK1,
concentrated in a 3 kDa molecular-mass cut-off filter device,
washed extensively with water and loaded on to a Mono Q column,
which did not bind ubiquitin, but did bind phospho-ubiquitin.
The latter was recovered by washing the column with 50 mM
Tris/HCl (pH 7.5), which was sufficient to elute stoichiometrically
phosphorylated ubiquitin. Similarly, Parkin Ubl domain (residues
1–76) was expressed as described previously [13] and was
phosphorylated with MBP–TcPINK1, recovered by filtration and
applied to a Mono Q column. Phospho-Parkin Ubl bound to the
column and eluted with approximately 100 mM NaCl. At least
60% purity was achieved.
Figure 1 Identification of a highly conserved ubiquitin phospho-Ser65
peptide upon PINK1 stimulation by CCCP in vivo
New highly conserved ubiquitin phospho-Ser65 peptide is up-regulated upon cell treatment with
CCCP. Flp-In T-Rex HEK-293 cells stably expressing FLAG-empty, wild-type PINK1–FLAG or
kinase-inactive PINK1–FLAG were grown in light, heavy and medium SILAC media respectively.
Cells under each condition were stimulated with 10 μM CCCP for 3 h. Subsequently, membrane
fractions were enriched by ultracentrifugation and solubilized in 1 % RapiGest. Lysates from each
of the three conditions were mixed at 1:1:1 and digested with trypsin before phosphopeptide
enrichment by HILIC (hydrophilic-interaction LC) and TiO2, and analysis by MS. Data analysis
was performed using MaxQuant. The experiment was performed using four replicates. (A)
Representative extracted ion chromatograms representing the ubiquitin Ser65) phosphopeptide
TLSDYNIQKEpSTLHLVLR in the three SILAC-labelled conditions. (B) Sequence alignment of
residues around Ser65 in human Parkin and ubiquitin in a variety of organisms showing a high
degree of conservation. C. elegans, Caenorhabditis elegans; D. melanogaster, Drosophila
melanogaster; H. sapiens, Homo sapiens; M. musculus, Mus musculus; S. cerevisiae,
Saccharomyces cerevisiae.
MALDI analysis
MALDI–TOF was used to confirm and establish the ratios
of phosphorylated compared with non-phosphorylated protein
species. An aliquot of the reaction (2 μl, 400–600 fmol) was added
to 2 μl of the matrix [2,5-dihydroxyacetophenone, 15 mg/ml in
80% ethanol and 20% 12 mg/ml ammonium citrate dibasic]
and 2 μl of 2% (v/v) trifluoroacetic acid was added before
spotting 0.5 μl of the sample on to an AnchorChip target
(Bruker Daltonics). The analysis was performed manually in
linear positive mode using an UltrafleXtreme (Bruker Daltonics)
MALDI–TOF mass spectrometer. For external calibration, six
average masses were used: insulin [M + H]+ avg (m/z 5734.520),
cytochrome c [M + 2H]2 + avg (m/z 6181.050), myoglobin
[M + 2H]2 + avg (m/z 8476.660), ubiquitin I [M + H]+ avg (m/z
8565.760) and cytochrome c [M + H] + avg (m/z 12360.970).
RESULTS
Overexpression of activated PINK1 in HEK-293 cells leads to
phosphorylation of ubiquitin at Ser65
We have previously reported that PINK1 is activated in
response to mitochondrial depolarization and that this leads
to autophosphorylation of PINK1 at Thr257 as well as
phosphorylation of Parkin at Ser65 in vivo [13]. To define
whether PINK1 may have additional substrates that are critical
for mediating PINK1 downstream signalling in response to
mitochondrial depolarization, we undertook a SILAC-based
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Figure 2 Ubiquitin is a direct substrate of TcPINK1 in vitro
(A) Sequence alignment of residues around Ser65 in human ubiquitin and a range of ubiquitin-like modifiers and Ubl-domain-containing human proteins. (B) Ubiquitin and Parkin are specific
substrates of TcPINK1. The indicated ubiquitin-like modifiers and Ubl-domain-containing proteins (1 μg) were incubated with wild-type (WT) or kinase-inactive (KI) TcPINK1 and Mg2 + -[γ -32P]ATP
for 60 min. Assays were terminated by the addition of SDS loading buffer and products were analysed by SDS/PAGE. Proteins were detected by Colloidal Coomassie Blue staining (top panel) and
incorporation of [γ -32P]ATP was detected by autoradiography (bottom panel). All substrates were of human sequence and expressed in E. coli. Tags on the substrates used for this experiment were
GST–OTU1, untagged Nedd8, untagged ISG15, His6–SUMO1-(1–97), ubiquilin2 (His6–SUMO tag cleaved off), His6–HOIL1 and USP4. Asterisks denote the correct substrate band. (C) TcPINK1 is
a specific upstream kinase of ubiquitin. The indicated kinases (1 μg) were incubated with ubiquitin and Mg2 + -[γ -32P]ATP for 60 min. Assays were terminated and analysed as described in (B).
Except for PINK1, all kinases were of human sequence and expression tags used were GST–MLK1-(132–413), GST–CDK2-(2–298)/cyclin A2-(171–432); His6–IKKε-(1–716), His6–IKKβ-(1–716),
His6–Aurora A-(2–403), His6–NUAK1-(2–660), His6–GSK3β-(2–420) and His6–PLK1-(1–603). Broken dividing lines indicate separate gels; asterisks denote the kinase band. The molecular mass
in kDa is indicated.
quantitative phosphoproteomic screen in Flp-In T-Rex HEK-
293 cells stably expressing FLAG empty, wild-type or kinase-
inactive PINK1–FLAG. Cells were stimulated with 10 μM
CCCP for 3 h to activate PINK1 and mitochondria-containing
membrane-enriched fractions were made and solubilized in 1%
RapiGest. Lysates were mixed from each cell condition at 1:1:1
before being subjected to tryptic digestion. Digested peptides
were subjected to phospho-peptide enrichment and analysis by
MS. The full analysis of the screen is available upon request
(C. Kondapalli, B. Dill, J. Proctor, A. Kazlauskaite, M. Trost
and M. Muqit, unpublished work). We strikingly identified a
novel ubiquitin phosphopeptide (TLSDYNIQKEpSTLHLVLR;
pS indicating that Ser65 on ubiquitin is phosphorylated) that
was significantly enriched 14-fold in stimulated mitochondrial
extracts of wild-type PINK1 compared with kinase-inactive
PINK1 across all four biological replicates (Figure 1A, and
Supplementary Figures S1 and S2 at http://www.biochemj.org/
bj/460/bj4600127add.htm). Multiple sequence alignment of this
region of ubiquitin revealed a high degree of conservation of this
phosphorylation site across all species (Figure 1B) and the peptide
also bears strong homology with the Parkin Ser65 peptide with a
hydrophobic residue at the − 4 position and histidine and valine
residues at the + 3 and + 5 positions respectively (Figure 1B).
Ubiquitin is a direct substrate of PINK1
We next investigated whether PINK1 could directly phosphorylate
ubiquitin and other ubiquitin-like modifiers or proteins that
contain a Ubl domain. Multiple sequence alignment identified
additional human proteins that contain a phosphorylatable serine
residue at the equivalent position to Parkin and ubiquitin
(Figure 2A). These include ubiquitin-like modifiers, Nedd8
and ISG15 (both domains), and Ubl-domain-containing proteins
including MIDN (midnolin), UBL4A, UBL7, USP48, USP9X
and USP9Y. We expressed a subset of ubiquitin-like modifiers
and Ubl-domain containing proteins with (ubiquitin, ISG15,
Nedd8, Parkin, Parkin Ubl domain) or without (OTU1, HOIL,
ubiquilin2, SUMO1) a predicted Ser65 residue and tested these
in phosphorylation assays with catalytically active recombinant
wild-type or kinase-inactive TcPINK1. Strikingly, ubiquitin was
phosphorylated directly by wild-type TcPINK1 to a degree similar
to the isolated Ubl domain of Parkin (Ubl) and greater than
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Figure 3 TcPINK1 phosphorylates ubiquitin at Ser65
(A) Mapping of phosphopeptide on ubiquitin after phosphorylation by TcPINK1 in vitro. Ubiquitin (10 μg) was incubated with 10 μg of either wild-type TcPINK1 or kinase-inactive TcPINK1 (D359A)
in the presence of Mg2 + -[γ -32P]ATP for 80 min. Assays were terminated by the addition of SDS loading buffer and products were separated by SDS/PAGE. Proteins were detected by Colloidal
Coomassie Blue staining and phosphorylated ubiquitin was digested with trypsin. Peptides were chromatographed on a reverse-phase HPLC Vydac C18 column equilibrated in 0.1 % trifluoroacetic
acid and the column developed with a linear acetonitrile gradient at a flow rate of 0.2 ml/min and fractions (0.1 ml each) were collected and analysed for 32P radioactivity by Cerenkov counting. One
major 32P-labelled peak was identified following incubation with wild-type TcPINK1, whereas no peaks were identified following incubation with kinase-inactive TcPINK1 (results not shown). (B) The
phosphopeptide identified in (A) was analysed by solid-phase Edman sequencing and MS. The amino acid sequence deduced from the single phosphopeptide seen in the LC–MS/MS analysis is
shown using the single-letter amino acid code. (C) The S65A mutation abolishes ubiquitin phosphorylation by TcPINK1. Wild-type or S65A mutant ubiquitin (1 μg) was incubated in the presence of
wild-type or kinase-inactive TcPINK1 (1 μg) and Mg2 + -[γ -32P]ATP for the times indicated and assays were terminated by the addition of SDS loading buffer. Samples were subjected to SDS/PAGE
and proteins detected by Colloidal Coomassie Blue staining (bottom panels) and incorporation of [γ -32P]ATP was detected by autoradiography (top panels). Cerenkov counting was used to calculate
the stoichiometry of ubiquitin phosphorylation indicated above autoradiographs as mol of [γ -32P]ATP incorporated/mol of ubiquitin. KI, kinase-inactive; WT, wild-type.
full-length Parkin (Figure 2B). No phosphorylation of these
proteins was seen with kinase-inactive TcPINK1. We also
observed phosphorylation of Nedd8, although this was
significantly less than that observed for ubiquitin (Figure 2B).
To investigate the specificity of ubiquitin phosphorylation by
PINK1, we compared the ability of eight other protein kinases
(MLK, CDK2, IKKε, IKKβ, Aurora kinase A, NUAK1, GSK3β
and PLK1) to phosphorylate ubiquitin. Using equimolar amounts
of ubiquitin we only observed significant phosphorylation of
ubiquitin by TcPINK1 and not any other kinase tested (Figure 2C).
PINK1 phosphorylates ubiquitin at Ser65 in vitro
To determine the site of ubiquitin phosphorylation by wild-type
TcPINK1, tryptic digests of 32P-labelled ubiquitin were analysed
by chromatography on a C18 column and one major 32P-labelled
phosphopeptide was observed (Figure 3A). A combination of
solid-phase Edman sequencing and MS revealed a peptide
phosphorylated at Ser65 (Figure 3B). We next undertook a time-
course analysis of ubiquitin phosphorylation by TcPINK1 and
observed robust time-dependent phosphorylation of ubiquitin
by wild-type TcPINK1 that was not observed by incubation
of kinase-inactive TcPINK1 (Figure 3C, left-hand panel). The
maximal stoichiometry of ubiquitin phosphorylation by TcPINK1
under our assay conditions was ∼0.11 mol of phosphate/mol of
protein (Figure 3C, left-hand panel). Importantly, mutation of
Ser65 to alanine abolished phosphorylation of ubiquitin by wild-
type TcPINK1 confirming that this residue is the major site of
PINK1 phosphorylation (Figure 3C, right-hand panel).
PINK1-dependent phosphorylation of ubiquitin activates
Ubl-Parkin E3 ligase activity
As outlined in the introduction, we recently reported that
incubating Parkin in the presence of wild-type PINK1, ubiquitin
and Mg2 + -ATP resulted in phosphorylation of Parkin at Ser65,
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Figure 4 PINK1-dependent phosphorylation of ubiquitin at Ser65 leads to increased activity of Ubl-Parkin
(A) MBP–TcPINK1 enhances Ubl-Parkin-mediated ubiquitin discharge from UbcH7. Ubl-Parkin was phosphorylated using wild-type (WT), kinase-inactive (KI) or no MBP–TcPINK1 in the
presence of Mg2 + -[γ -32P]ATP. An E2-discharge assay was established by incubation of this mixture with 2 μg of UbcH7 that had been pre-incubated with E1 and FLAG–ubiquitin in the presence
of ATP for 60 min. Reactions were allowed to continue for 15 min and were stopped using SDS loading buffer in the absence of reducing agent. Samples were analysed as described in the Materials
and methods section. Protein phosphorylation was monitored by autoradiography (bottom panel). (B) Ubl-Parkin activity is increased by wild-type TcPINK1. A 2 μg amount of full-length (WT)
or Ubl-Parkin was incubated with 1 μg of wild-type (WT), kinase-inactive (KI) or no TcPINK1 in a kinase reaction for 60 min. The ubiquitylation reactions were then initiated by the addition of
ubiquitylation assay components (E1, UbcH7 and FLAG–ubiquitin) and 2 μg of His6–SUMO-Miro1. Reactions were terminated after 60 min by the addition of SDS loading buffer and products
were analysed by SDS/PAGE. Miro1, ubiquitin (Ub) and Parkin were detected using anti-SUMO, anti-FLAG and anti-Parkin antibodies respectively. (C) Activation of Ubl-Parkin by TcPINK1 is
abolished by S65A ubiquitin. Ubl-Parkin was incubated in the presence or absence of wild-type (WT) or kinase-inactive (KI) PINK1. The ubiquitylation reactions were then initiated by the addition
of ubiquitylation assay components including 0.04 mM wild-type (WT) or S65A His6–FLAG–ubiquitin. Reactions were terminated after 60 min by the addition of SDS loading buffer and products
were analysed by SDS/PAGE. Miro1, ubiquitin and Parkin were detected using anti-SUMO, anti-FLAG and anti-Parkin antibodies respectively. The molecular mass in kDa is indicated.
which was accompanied by a marked stimulation of Parkin E3
ligase activity [13,27]. In the light of the finding that PINK1
phosphorylates ubiquitin at Ser65, we decided to explore whether
the ability of PINK1 to activate Parkin was dependent on the
presence of phosphorylated ubiquitin. We initially studied a
fragment of Parkin that lacks the Ubl domain and hence Ser65
(residues 80–465; Ubl-Parkin) and which therefore cannot
be directly phosphorylated by PINK1. We and other groups
[23,27,28] have previously demonstrated that this fragment
exhibits enhanced basal E3 ligase activity compared with full-
length non-phosphorylated Parkin. We investigated whether
addition of PINK1 in the presence of Mg2 + -ATP and ubiquitin
(which would lead to the production of Ser65-phosphorylated
ubiquitin) could lead to enhanced activation of Ubl-Parkin using
a recently established E2-ubiquitin discharge assay in which the
hydrolysis of UbcH7 conjugated to ubiquitin is monitored on a
Coomassie Blue-stained gel [27]. Using this assay, we observed
that addition of Ubl-Parkin alone in the absence of PINK1 only
caused mild E2-ubiquitin discharge, consistent with its moderate
constitutive activity (Figure 4A, lanes 3 and 4). However, upon
addition of wild-type, but not kinase-inactive, TcPINK1, we
observed striking discharge of ubiquitin from UbcH7 (Figure 4A,
lanes 5 and 6). The E2-discharge assay was conducted using
0.1 mM [γ -32P]ATP and autoradiographs revealed significant
ubiquitin phosphorylation and TcPINK1 autophosphorylation
during the reaction; no significant phosphorylation of
any other component was observed (Figure 4A, bottom
panel).
In addition to the E2-discharge assay, in our previous work
we also assessed Parkin E3 ligase activity by monitoring the
formation of free polyubiquitin chains, as well as the multi-
mono-ubiquitylation of the substrate Miro1 [27]. In agreement
with previous data, we observed marked activation of full-length
Parkin E3 ligase activity when incubated with wild-type, but
not kinase-inactive, PINK1 in the presence of ubiquitin and
Mg2 + -ATP as judged by the formation of free polyubiquitin
chains and Miro1 multi-mono-ubiquitylation (Figure 4B, lanes
1 and 2). Moreover, consistent with previous work [23,27,28],
Ubl-Parkin in the absence of PINK1 displayed significant
basal polyubiquitylation activity (Figure 4B, lanes 9 and 10).
Interestingly, upon incubation with wild-type, but not kinase-
inactive, TcPINK1, we observed further substantial activation
of Ubl-Parkin as judged by high-molecular-mass polyubiquitin
chain formation and auto-ubiquitylation of Parkin (Figure 4B,
lanes 5 and 6). It should be noted that, in contrast with full-
length Parkin, we found that Ubl-Parkin did not catalyse
Miro1 multi-mono-ubiquitylation when incubated with wild-type
PINK1 (Figure 4B), indicating that the Ubl domain may be
required for optimal substrate ubiquitylation.
We next sought to determine whether activation of Ubl-Parkin
mediated by wild-type PINK1 was dependent on phosphorylation
of ubiquitin at Ser65. We therefore repeated the Ubl-Parkin
ubiquitylation assays described above in the presence of either
wild-type or S65A mutant ubiquitin. Strikingly we observed a
dramatic reduction in the activity of Ubl-Parkin pre-incubated
with wild-type PINK1 when using S65A mutant ubiquitin in the
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Figure 5 Phosphorylation of Parkin at Ser65 and ubiquitin at Ser65 are
necessary for full activation by PINK1
Full-length (WT) and S65A Parkin were incubated in the presence or absence of wild-type (WT)
or kinase-inactive (KI) PINK1 in a kinase reaction. The ubiquitylation reactions were then initiated
by the addition of ubiquitylation assay components including 0.04 mM wild-type (WT) or S65A
His6–FLAG–ubiquitin. Miro1, ubiquitin and Parkin were detected using anti-SUMO, anti-FLAG
and anti-Parkin antibodies respectively. Miro1-Ub, ubiquitylated Miro1. The molecular mass in
kDa is indicated.
ubiquitylation assay (Figure 4C, lanes 3 and 4) compared with
using wild-type ubiquitin (Figure 4C, lanes 1 and 2).
Evidence for dual requirement of PINK1-dependent
phosphorylation of Parkin at Ser65 and ubiquitin at Ser65 in
mediating optimal activation of full-length Parkin E3 ligase activity
We next investigated the role for PINK1-dependent phosphoryla-
tion of ubiquitin at Ser65 in the activation of full-length Parkin
following TcPINK1 phosphorylation. Upon incubation of full-
length Parkin with wild-type TcPINK1, ubiquitin and Mg2 + -
ATP we observed maximal Parkin ubiquitylation activity as
judged by the generation of free polyubiquitin chains and
multi-mono-ubiquitylation of Miro1 (Figure 5, lanes 1 and 2).
The absolute dependence of Parkin on wild-type PINK1 for
activation is confirmed by the absence of activity when Parkin
is pre-incubated with kinase-inactive PINK1 (Figure 5, lanes
5 and 6). In the presence of a S65A mutant of ubiquitin, we
observed a substantial decrease in Parkin E3 ligase activity;
however, it was not completely abolished as judged by Miro1
ubiquitylation (Figure 5, lanes 3 and 4) as opposed to Parkin
that was pre-incubated with kinase-inactive PINK1 (Figure 4C,
lanes 7 and 8). Moreover, as we have previously reported [13,27],
the Parkin S65A mutant led to near complete loss of Parkin
activity as judged by loss of both Miro1 substrate ubiquitylation
and free chain formation. We did observe high-molecular-mass
polyubiquitylation (Figure 5, lanes 9 and 10) indicating residual
activity. That either the S65A ubiquitin mutant or the Parkin
S65A mutant alone can substantially reduce, but not abolish,
Parkin E3 ligase activity indicates that both PINK1-dependent
phosphorylation of Parkin at Ser65 and ubiquitin at Ser65 are
required for mediating optimal activation of Parkin E3 ligase
activity. Conversely we only observed complete loss of Parkin
activity upon incubation of both S65A ubiquitin with S65A Parkin
pre-incubated with wild-type TcPINK1 (Figure 5, lanes 11 and
12), similar to incubation of S65A Parkin pre-incubated with
kinase-inactive TcPINK1 (Figure 5, lanes 13–16).
Purified Ser65-phosphorylated ubiquitin and Ser65-phosphorylated
Ubl domain of Parkin can directly and differentially activate Parkin
E3 ligase activity
To provide stronger evidence that ubiquitin phosphorylated at
Ser65 can directly activate Parkin E3 ligase activity, we next
investigated whether addition of purified Ser65-phosphorylated
ubiquitin (ubiquitinPhospho−Ser65) and/or the Ser65-phosphorylated
isolated Ubl domain of Parkin (residues 1–76) (UblPhospho−Ser65)
could directly activate Parkin E3 ligase activity without the
presence of wild-type PINK1. Milligram amounts of ubiquitin
and the Ubl domain of Parkin (His6–SUMO tag cleaved)
were phosphorylated by MBP–TcPINK1. MBP–TcPINK1 was
then removed using a Centricon centrifugal high-molecular-
mass filter and the reaction mixture was subjected to ion-
exchange chromatography. We were able to successfully isolate
100% pure ubiquitinPhospho−Ser65 and non-phosphorylated ubiquitin
to homogeneity and confirmed their identity and purity by
MS (Figure 6A). We were able to purify at least 60%
pure UblPhospho−Ser65 (Figure 6B). Importantly, they were free of
TcPINK1.
We next assessed whether ubiquitinPhospho−Ser65 and/or
UblPhospho−Ser65 could directly influence the activity of Parkin.
We therefore performed Miro1 substrate ubiquitylation assays
of either full-length wild-type or Ubl-Parkin (∼0.8 μM)
in the absence of TcPINK1 and investigated the effect
of adding increasing amounts of ubiquitinPhospho−Ser65 or non-
phosphorylated ubiquitin (0.04, 0.2, 1 and 5 μg). In the absence of
ubiquitinPhospho−Ser65 we observed no activity of full-length Parkin
(Figure 7A, lanes 1 and 6) and moderate basal activity of Ubl-
Parkin (Figure 7A, lanes 11 and 16). Upon addition of increasing
amounts of ubiquitinPhospho−Ser65 we observed striking activation
of both full-length Parkin (Figure 7A, lanes 7–10) and Ubl-
Parkin (Figure 7A, lanes 17–20) as judged by the formation of
polyubiquitin chains, increased auto-ubiquitylation and Miro1
ubiquitylation. Importantly, we observed no activation of full-
length Parkin (Figure 7A, lanes 2–5) or Ubl-Parkin (Figure 7A,
lanes 12–15) following the addition of an equivalent amount of
non-phosphorylated ubiquitin.
Interestingly, we observed differential sensitivity of full-length
Parkin and Ubl-Parkin to the effect of ubiquitinPhospho−Ser65.
Addition of 0.04 μg (∼0.1 μM) of ubiquitinPhospho−Ser65 led to
activation of Ubl-Parkin (Figure 7A, lane 17), but this
amount did not have any significant effect on full-length Parkin
(Figure 7A, lane 7). Furthermore, addition of the increasing
amounts of ubiquitinPhospho−Ser65 led to a striking differential profile
in the nature of the poly-auto-ubiquitylation catalysed by Ubl-
Parkin with intermediate-sized chains formed on addition 0.04 μg
or 0.2 μg of ubiquitinPhospho−Ser65 (Figure 7A, lanes 17 and 18) and
high-molecular-mass long chains on addition of 1 (∼2.5 μM) or
5 (∼12 μM) μg of ubiquitinPhospho−Ser65 (Figure 7A, lanes 19 and
20). Moreover, we also observed that addition of molar excess
amounts of ubiquitinPhospho−Ser65 (relative to Ubl-Parkin) enabled
Ubl-Parkin to detectably catalyse mono-ubiquitylation of Miro1
(Figure 7A, lanes 19 and 20).
We then investigated the role that UblPhospho−Ser65 had on
Parkin activity. Interestingly, addition of increasing amounts
of UblPhospho−Ser65 (0.04, 0.2, 1 and 5 μg) had no significant
effect on the activation of full-length Parkin (Figure 7B, lanes
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Figure 6 Quality control of phosphorylated Ubl (Parkin residues 1–76) and phosphorylated ubiquitin
(A) MALDI–TOF spectra of non-phospho-ubiquitin (top panel) and phospho-Ser65 ubiquitin (bottom panel) after incubation with MBP–PINK1 after separation on a Mono Q column. (B) MALDI–TOF
spectra of non-phosphorylated Ubl (Parkin residues 1–76) (top panel) and mixed Ubl species (∼60 % phosphorylated and ∼40 % non-phosphorylated) (bottom panel). (A and B) In total, 2 μg of
the non-phospho-ubiquitin and phospho-ubiquitin (A) or non-phospho-Ubl and phospho-Ser65 Ubl (B) were resolved by SDS/PAGE, followed by staining with Colloidal Coomassie Blue for quality
control.
7–10). In contrast, addition of UblPhospho−Ser65 induced a striking
increase in activity of Ubl-Parkin as judged by polyubiquitin
chain formation, increased auto-ubiquitylation and Miro1 mono-
ubiquitylation (Figure 7B, lanes 17–20) similar to the effects
induced by ubiquitinPhospho−Ser65.
Purified Ser65-phosphorylated ubiquitin and Ser65-phosphorylated
Ubl domain of Parkin can directly and differentially stimulate
Parkin to discharge ubiquitin from UbcH7-loaded E2 ligase
We next evaluated the ability of purified ubiquitinPhospho−Ser65 or
UblPhospho−Ser65 to stimulate Parkin to discharge ubiquitin from
UbcH7-loaded E2 ligase in the absence of TcPINK1 as another
read-out of Parkin E3 ligase activity. In these studies we
investigated the ability of a fixed amount of ubiquitinPhospho−Ser65
or non-phosphorylated ubiquitin (1 μg) to stimulate wild-type
full-length Parkin, a S65A mutant of full-length Parkin, as well
as Ubl-Parkin to discharge ubiquitin from the loaded UbcH7.
Addition of full-length Parkin alone to the ubiquitin-loaded E2
reaction did not promote E2-ubiquitin discharge (Figure 8A, lanes
2 and 3). However, addition of ubiquitinPhospho−Ser65 led to striking
and maximal E2-ubiquitin discharge (Figure 8A, lanes 4 and 5)
that was not observed following addition of non-phosphorylated
ubiquitin (Figure 8A, lanes 6 and 7). Addition of Ubl-Parkin
alone promoted slight E2-ubiquitin discharge (Figure 8A, lanes 8
and 9), but addition of ubiquitinPhospho−Ser65, triggered significantly
increased E2-ubiquitin discharge (Figure 8A, lanes 10 and 11) that
was not seen with the addition of non-phosphorylated ubiquitin
(Figure 8A, lanes 12 and 13).
Interestingly, analysis of the Parkin S65A mutant revealed
similar results to those of wild-type Parkin: we observed maximal
discharge of E2-ubiquitin by S65A Parkin on addition of
ubiquitinPhospho−Ser65 (Figure 8A, lanes 16 and 17), but not with non-
phosphorylated ubiquitin (Figure 8A, lanes 18 and 19), indicating
that, under the assay conditions used, ubiquitinPhospho−Ser65 alone is
sufficient to activate even the S65A Parkin mutant.
We next tested the ability of UblPhospho−Ser65 to stimulate
Parkin to discharge ubiquitin from UbcH7-loaded E2 ligase.
Consistent with our analysis of the effect of UblPhospho−Ser65 on
Parkin ubiquitylation (Figure 7B), we observed that UblPhospho−Ser65
(∼5 μM) failed to stimulate full-length Parkin to discharge
ubiquitin (Figure 8B, lanes 4 and 5). In contrast, UblPhospho−Ser65
markedly stimulated Ubl-Parkin to promote E2-ubiquitin
discharge (Figure 8B, lanes 10 and 11), compared with Ubl-
Parkin alone (Figure 8B, lanes 8 and 9) or Ubl-Parkin in
combination with non-phosphorylated Ubl (Figure 8B, lanes 12
and 13). Similar to full-length wild-type Parkin, we observed
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Figure 7 Full-length wild-type Parkin is activated by ubiquitinPhospho−Ser65, and Ubl-Parkin is activated by ubiquitinPhospho−Ser65 and UblPhospho−Ser65
(A) Full-length wild-type (WT) and Ubl-Parkin are activated by ubiquitinPhospho−Ser65. A 2 μg amount of full-length (WT), S65A or Ubl-Parkin was incubated with the ubiquitylation assay
components (E1 and UbcH7) in the presence of 0.05 mM ubiquitin. The ubiquitin used in these assays was a mixture of FLAG–ubiquitin and untagged phospho- or non-phospho-ubiquitin as
indicated (total of 25 μg per reaction). Reactions were terminated after 60 min by the addition of SDS loading buffer and products were analysed by SDS/PAGE. Miro1, ubiquitin and Parkin were
detected using anti-SUMO, anti-FLAG and anti-Parkin antibodies respectively. Formation of short, intermediate and long polyubiquitylated species is indicated by square brackets. P-ubiquitin,
ubiquitinPhospho−Ser65. (B) UblPhospho−Ser65 activates Ubl-Parkin, but not full-length Parkin. Reactions were carried out as described in (A), but the 0.05 mM FLAG–ubiquitin was used in all reactions
and phospho- or non-phospho-Ubl domain (Parkin residues 1–76) was added as indicated. P-Ubl, UblPhospho−Ser65. The molecular mass in kDa is indicated.
that UblPhospho−Ser65 could not stimulate the S65A Parkin mutant to
promote E2-ubiquitin discharge (Figure 8B, lanes 16 and 17).
DISCUSSION
How Parkin is activated has been a major question since the
discovery that Parkin is autoinhibited via interaction between
the N-terminal Ubl domain and the C-terminal portion of the
protein [23]. We have previously reported that PINK1-dependent
phosphorylation of Parkin Ser65 that lies within the Ubl domain
stimulates Parkin E3 ligase activity [13]. Recent high-resolution
crystal structures of Parkin that were mainly solved without the
Ubl domain have not provided much insight into how Parkin is
activated by PINK1 [14–16]. In the present paper we describe
a crucial discovery that PINK1-dependent phosphorylation of
ubiquitin at Ser65 plays a critical role in mediating Parkin
activation. Our data indicate that ubiquitinPhospho−Ser65 is a direct
and potent activator of Parkin (Figures 7 and 8). Our studies
with purified ubiquitinPhospho−Ser65 also demonstrate that the Ubl-
Parkin requires smaller amounts of ubiquitinPhospho−Ser65 compared
with full-length Parkin for activation (Figure 7). This might
be consistent with a two-step activation mechanism of Parkin
in which an initial phosphorylation of Parkin Ser65 by PINK1
within the Ubl domain would lead to disruption of the interaction
of the Ubl domain and C-terminus of Parkin that could then prime
Parkin for optimal binding and activation by ubiquitinPhospho−Ser65
(Figure 9).
Previous work has revealed that the Ubl domain of Parkin
interacts with high affinity with the C-terminal catalytic domain
[23]. Ser65 on the Ubl domain lies within the fifth β-strand and
phosphorylation could perturb the β-strand formation around
this region [29–32]. This could reduce affinity of the Ser65-
phosphorylated Ubl domain for the catalytic region of Parkin,
thereby opening up the Parkin structure and making it more
readily activated by ubiquitinPhospho−Ser65. Such a priming model
is well established for many protein kinases, e.g. for AGC kinases
such as Akt1. Here Akt1 binds to the PtdIns(3,4,5)P3 second
messenger produced by activation of PI3K (phosphoinositide 3-
kinase). This does not directly activate Akt, but instead induces a
conformational change that exposes the activating Thr308, priming
it for phosphorylation by the upstream 3-phosphoinositide-
dependent kinase 1 [33]. To our knowledge the only report
for a potential priming mechanism for an RING E3 ligases is
for the CBL-B RING E3 ligase, in which phosphorylation of
Tyr363 that lies in a linker region away from the canonical RING
domain plays a critical priming step to increase CBL-B activity
via improving the efficiency of ubiquitin transfer from the E2
[34]. To support our priming model, in future work, it would
be interesting to test whether purified PINK1-induced Ser65-
phosphorylated wild-type full-length Parkin (in which the PINK1
has been removed) exhibits enhanced sensitivity to the activating
effect of ubiquitinPhospho−Ser65 compared with non-phosphorylated
c© 2014 The Author(s) The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Licence (CC-BY) (http://creativecommons.org/licenses/by/3.0/) which
permits unrestricted use, distribution and reproduction in any medium, provided the original work is properly cited.
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Figure 8 Differential effects of ubiquitinPhospho−Ser65 and UblPhospho−Ser65 on
ubiquitin discharge by full-length wild-type, S65A and Ubl-Parkin
(A) UbiquitinPhospho−Ser65 leads to activation of full-length wild-type, S65A and Ubl-Parkin
and increased ubiquitin discharge. An E2-discharge assay was established by incubation
of full-length (WT), S65A or Ubl-Parkin in the presence or absence of phospho- or
non-phospho-ubiquitin (1 μg) as indicated with 2 μg of UbcH7 that had been pre-incubated
with E1 and FLAG–ubiquitin in the presence of Mg2 + -ATP for 60 min. Reactions were
allowed to continue for 15 min and were stopped using SDS loading buffer in the absence
of reducing agent. The reaction products were resolved using SDS/PAGE and the proteins were
visualised by Colloidal Coomassie Blue staining. (B) UblPhospho−Ser65 leads to activation and
increased ubiquitin discharge by Ubl-Parkin, but does not affect the full-length wild-type
and S65A Parkin. The assays were carried out as described above, but phospho- and
non-phospho-Ubl were added to the reactions as indicated. P-ubiquitin, ubiquitinPhospho−Ser65;
P-Ubl, UblPhospho−Ser65. The molecular mass in kDa is indicated.
Parkin. We have also recently identified a missense mutant of
Parkin, R33Q, that lies within the Ubl domain which enables it to
be phosphorylated to a significantly greater degree than wild-type
Parkin and this is associated with increased E3 ligase activity [27].
It would be interesting to determine whether its enhanced activity
was due to increased sensitivity to ubiquitinPhospho−Ser65.
Our findings also predict that there will be a ubiquitinPhospho−Ser65-
binding pocket within the catalytic core of Parkin that would
induce a conformational change to activate Parkin following
the ubiquitinPhospho−Ser65 interaction. Recent structural analysis of
Parkin has predicted a putative phosphopeptide-binding pocket
within the RING0 domain that is formed by three positively
charged residues, Lys161, Arg163 and Lys211 [15]. In the future
it will be important to undertake binding studies and activation
assays to determine whether mutation of these residues disrupts
the ability of ubiquitinPhospho−Ser65 to bind to Parkin and become
activated by PINK1.
We also observed a differential effect of the UblPhospho−Ser65 in
its ability to activate Parkin. In contrast with ubiquitinPhospho−Ser65,
UblPhospho−Ser65 was unable to activate full-length Parkin. We
cannot rule out the possibility that this observation is due to
the UblPhospho−Ser65 protein used being only 60% phosphorylated
compared with ubiquitinPhospho−Ser65 which was stoichiometrically
phosphorylated. However, we believe that this is unlikely since
the UblPhospho−Ser65 was still capable of activating Ubl-Parkin to a
similar degree as ubiquitinPhospho−Ser65. An alternative explanation
may be that the binding pocket for UblPhospho−Ser65 is distinct
from that of ubiquitinPhospho−Ser65 and not accessible due to steric
hindrance imposed by the non-phosphorylated Ubl domain. We
hypothesize that phosphorylation of Parkin at Ser65 would lead to
release of this Ubl-mediated steric hindrance. This is supported by
our observation that PINK1-induced phosphorylation of Parkin
can still activate E3 ligase activity in the presence of S65A
ubiquitin as judged by Miro1 ubiquitylation and this is abolished
by the Parkin S65A mutant (Figure 5). It would be interesting
to test this in future activation studies with of UblPhospho−Ser65
with phosphorylated Parkin. It would also be interesting to
map and compare the region of interaction of UblPhospho−Ser65 and
Parkin with that of ubiquitinPhospho−Ser65. Further characterization
of the ubiquitinPhospho−Ser65/UblPhospho−Ser65 pocket on Parkin would
be worthwhile as it might provide insights into how to generate
small molecules that could bind to this site to activate Parkin. As
loss-of-function mutations in PINK1 or Parkin cause PD, it would
be fascinating to explore whether compounds that could bind to
this site and activate Parkin would have therapeutic potential.
There is increasing evidence of a strong interplay between
protein phosphorylation and protein ubiquitylation [35,36], but
the discovery that PINK1 directly targets ubiquitin at Ser65 is
perhaps the starkest example of how these two major systems
of post-translational modifications converge. To our knowledge
this is the first report of the identification of ubiquitinPhospho−Ser65.
Previously large-scale phosphoproteomic screens have uncovered
other phosphorylation sites of ubiquitin including Thr7 and
Thr12 [37], Ser57 [38,39] and Tyr59 [40]; however, the functional
consequences of phosphorylation of these sites on ubiquitin
function is unknown, and neither is the identity of the upstream
kinases for these sites known. Our discovery of ubiquitinPhospho−Ser65
raises many exciting future questions including whether it can
be assembled in ubiquitin chains in a similar fashion to non-
phosphorylated ubiquitin, whether E2 ligases can be charged
with ubiquitinPhospho−Ser65, and whether other RING or RING-IBR-
RING E3 ligases can use or be activated by ubiquitinPhospho−Ser65.
Specifically it is interesting that Ser65 of ubiquitin lies close
to Lys63 which forms a major ubiquitin linkage type. In future
work it would be worth investigating whether phosphorylation
at Ser65 of ubiquitin has an impact on its ability to form Lys63
chains and conversely whether dimeric or multimeric Lys63 chains
composed of ubiquitinPhospho−Ser65 alters their sensitivity to Lys63-
specific deubiquitinases such as AMSH-like protease [41].
Overall our studies have identified PINK1 as an upstream
kinase of ubiquitin Ser65 and revealed a critical requirement of
ubiquitinPhospho−Ser65 in mediating the activation of Parkin E3 ligase
activity. Our work provides further mechanistic detail on the
regulation of Parkin and suggests a dual mechanism in which both
the Ser65-phosphorylated Ubl domain and ubiquitinPhospho−Ser65 are
required for optimal Parkin activation. We also provide in vivo
evidence that ubiquitin phosphorylation at Ser65 is regulated by
PINK1 and it would be interesting to identify substrates in vivo
that are modified by ubiquitinPhospho−Ser65 as these could represent
physiological substrates of Parkin. Our findings also indicate that
small molecules that mimic ubiquitinPhospho−Ser65 could be beneficial
in activating Parkin as a potential therapy for PD patients.
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Figure 9 Model of Parkin activation by PINK1 and phospho-ubiquitin
Under basal conditions Parkin exists in a closed inactive conformation, in part mediated by Ubl-mediated autoinhibition. Upon mitochondrial depolarization, induced by the uncoupler CCCP,
PINK1 becomes activated and phosphorylates Parkin and ubiquitin at Ser65. Phosphorylation of Parkin relieves the Ubl-mediated autoinhibition and primes Parkin for optimal binding by
phospho-Ser65-ubiquitin and activation of Parkin E3 ligase activity.
AUTHOR CONTRIBUTION
Agne Kazlauskaite performed most of the experiments. Chandana Kondapalli and
Matthias Trost performed the phosphoproteomic screen and analysis. Axel Knebel
expressed and purified phospho-ubiquitin and the phospho-Ubl domain of Parkin. Robert
Gourlay, David Campbell and Maria Stella Ritorto undertook MS analysis. Kay Hofmann
undertook bioinformatics and multiple sequence alignment analysis. Miratul Muqit, Agne
Kazlauskaite and Dario Alessi planned experiments and analysed the data. Miratul Muqit
and Agne Kazlauskaite wrote the paper with further contributions from all of the authors.
Miratul Muqit supervised the project.
ACKNOWLEDGEMENTS
We thank the Sequencing Service (College of Life Sciences, University of Dundee, Dundee,
Scotland, U.K.) and James Hastie and Hilary McLauchlan and the antibody purification
and protein production teams [DSTT (Division of Signal Transduction Therapy), University
of Dundee, Dundee, Scotland, U.K.] for excellent technical support. We thank Ubiquigent
for provision of ubiquitin reagents including E2 and E1 enzymes.
FUNDING
This work was supported by the Medical Research Council (MRC), the Wellcome Trust,
Parkinson’s UK, the Michael J. Fox Foundation for Parkinson’s disease research, and a
Wellcome Trust/Medical Research Council (MC) PD (Parkinson’s disease) consortium
grant to University College London (UCL) Institute of Neurology, University of Sheffield
and the MRC Protein Phosphorylation and Ubiquitylation Unit of the University of Dundee.
A.K. is funded by a J. Macdonald Menzies Charitable Trust Prize Studentship. M.M.K.M. is
funded by a Wellcome Trust Senior Research Fellowship in Clinical Science [grant number
101022/Z/13/Z]. We also thank the pharmaceutical companies supporting the Division of
Signal Transduction Therapy Unit (AstraZeneca, Boehringer-Ingelheim, GlaxoSmithKline,
Merck KGaA, Janssen Pharmaceutica and Pfizer) for financial support.
REFERENCES
1 Kitada, T., Asakawa, S., Hattori, N., Matsumine, H., Yamamura, Y., Minoshima, S.,
Yokochi, M., Mizuno, Y. and Shimizu, N. (1998) Mutations in the parkin gene cause
autosomal recessive juvenile parkinsonism. Nature 392, 605–608 CrossRef PubMed
2 Valente, E. M., Abou-Sleiman, P. M., Caputo, V., Muqit, M. M., Harvey, K., Gispert, S., Ali,
Z., Del Turco, D., Bentivoglio, A. R., Healy, D. G. et al. (2004) Hereditary early-onset
Parkinson’s disease caused by mutations in PINK1. Science 304,
1158–1160 CrossRef PubMed
3 Lucking, C. B., Durr, A., Bonifati, V., Vaughan, J., De Michele, G., Gasser, T., Harhangi,
B. S., Meco, G., Denefle, P., Wood, N. W. et al. (2000) Association between early-onset
Parkinson’s disease and mutations in the parkin gene. N. Engl. J. Med. 342,
1560–1567 CrossRef
4 Khan, N. L., Graham, E., Critchley, P., Schrag, A. E., Wood, N. W., Lees, A. J., Bhatia, K. P.
and Quinn, N. (2003) Parkin disease: a phenotypic study of a large case series. Brain
126, 1279–1292 CrossRef PubMed
5 Khan, N. L., Valente, E. M., Bentivoglio, A. R., Wood, N. W., Albanese, A., Brooks, D. J.
and Piccini, P. (2002) Clinical and subclinical dopaminergic dysfunction in PARK6-linked
parkinsonism: an 18F-dopa PET study. Ann. Neurol. 52, 849–853 CrossRef PubMed
6 Clark, I. E., Dodson, M. W., Jiang, C., Cao, J. H., Huh, J. R., Seol, J. H., Yoo, S. J., Hay,
B. A. and Guo, M. (2006) Drosophila pink1 is required for mitochondrial function and
interacts genetically with parkin. Nature 441, 1162–1166 CrossRef PubMed
7 Park, J., Lee, S. B., Lee, S., Kim, Y., Song, S., Kim, S., Bae, E., Kim, J., Shong, M., Kim,
J. M. and Chung, J. (2006) Mitochondrial dysfunction in Drosophila PINK1 mutants is
complemented by parkin. Nature 441, 1157–1161 CrossRef PubMed
8 Yang, Y., Gehrke, S., Imai, Y., Huang, Z., Ouyang, Y., Wang, J. W., Yang, L., Beal, M. F.,
Vogel, H. and Lu, B. (2006) Mitochondrial pathology and muscle and dopaminergic
neuron degeneration caused by inactivation of Drosophila Pink1 is rescued by Parkin.
Proc. Natl. Acad. Sci. U.S.A. 103, 10793–10798 CrossRef PubMed
9 Matsuda, N., Sato, S., Shiba, K., Okatsu, K., Saisho, K., Gautier, C. A., Sou, Y. S., Saiki,
S., Kawajiri, S., Sato, F. et al. (2010) PINK1 stabilized by mitochondrial depolarization
recruits Parkin to damaged mitochondria and activates latent Parkin for mitophagy. J. Cell
Biol. 189, 211–221 CrossRef PubMed
c© 2014 The Author(s) The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Licence (CC-BY) (http://creativecommons.org/licenses/by/3.0/) which
permits unrestricted use, distribution and reproduction in any medium, provided the original work is properly cited.
Ser65-phosphorylated ubiquitin activates Parkin 139
10 Narendra, D. P., Jin, S. M., Tanaka, A., Suen, D. F., Gautier, C. A., Shen, J., Cookson,
M. R. and Youle, R. J. (2010) PINK1 is selectively stabilized on impaired mitochondria to
activate Parkin. PLoS Biol. 8, e1000298 CrossRef PubMed
11 Vives-Bauza, C., Zhou, C., Huang, Y., Cui, M., de Vries, R. L., Kim, J., May, J., Tocilescu,
M. A., Liu, W., Ko, H. S. et al. (2010) PINK1-dependent recruitment of Parkin to
mitochondria in mitophagy. Proc. Natl. Acad. Sci. U.S.A. 107,
378–383 CrossRef PubMed
12 Geisler, S., Holmstrom, K. M., Skujat, D., Fiesel, F. C., Rothfuss, O. C., Kahle, P. J. and
Springer, W. (2010) PINK1/Parkin-mediated mitophagy is dependent on VDAC1 and
p62/SQSTM1. Nat. Cell Biol. 12, 119–131 CrossRef PubMed
13 Kondapalli, C., Kazlauskaite, A., Zhang, N., Woodroof, H. I., Campbell, D. G., Gourlay, R.,
Burchell, L., Walden, H., Macartney, T. J., Deak, M. et al. (2012) PINK1 is activated by
mitochondrial membrane potential depolarization and stimulates Parkin E3 ligase activity
by phosphorylating Serine 65. Open Biol. 2, 120080 CrossRef PubMed
14 Riley, B. E., Lougheed, J. C., Callaway, K., Velasquez, M., Brecht, E., Nguyen, L., Shaler,
T., Walker, D., Yang, Y., Regnstrom, K. et al. (2013) Structure and function of Parkin E3
ubiquitin ligase reveals aspects of RING and HECT ligases. Nat. Commun. 4,
1982 CrossRef PubMed
15 Wauer, T. and Komander, D. (2013) Structure of the human Parkin ligase domain in an
autoinhibited state. EMBO J. 32, 2099–2112 CrossRef PubMed
16 Trempe, J. F., Sauve, V., Grenier, K., Seirafi, M., Tang, M. Y., Menade, M.,
Al-Abdul-Wahid, S., Krett, J., Wong, K., Kozlov, G. et al. (2013) Structure of parkin reveals
mechanisms for ubiquitin ligase activation. Science 340, 1451–1455 CrossRef PubMed
17 Yamano, K. and Youle, R. J. (2013) PINK1 is degraded through the N-end rule pathway.
Autophagy 9, 1758–1769 CrossRef PubMed
18 Ubersax, J. A. and Ferrell, Jr, J. E. (2007) Mechanisms of specificity in protein
phosphorylation. Nat. Rev. Mol. Cell Biol. 8, 530–541 CrossRef PubMed
19 Thingholm, T. E., Jorgensen, T. J., Jensen, O. N. and Larsen, M. R. (2006) Highly
selective enrichment of phosphorylated peptides using titanium dioxide. Nat. Protoc. 1,
1929–1935 CrossRef PubMed
20 Trost, M., English, L., Lemieux, S., Courcelles, M., Desjardins, M. and Thibault, P. (2009)
The phagosomal proteome in interferon-γ -activated macrophages. Immunity 30,
143–154 CrossRef PubMed
21 Cox, J. and Mann, M. (2008) MaxQuant enables high peptide identification rates,
individualized p.p.b.-range mass accuracies and proteome-wide protein quantification.
Nat. Biotechnol. 26, 1367–1372 CrossRef PubMed
22 Woodroof, H. I., Pogson, J. H., Begley, M., Cantley, L. C., Deak, M., Campbell, D. G.,
van Aalten, D. M. F., Whitworth, A. J., Alessi, D. R. and Muqit, M. M. K. (2011) Discovery
of catalytically active orthologues of the Parkinson’s disease kinase PINK1: analysis of
substrate specificity and impact of mutations. Open Biology. 1, 110012 CrossRef PubMed
23 Chaugule, V. K., Burchell, L., Barber, K. R., Sidhu, A., Leslie, S. J., Shaw, G. S. and
Walden, H. (2011) Autoregulation of Parkin activity through its ubiquitin-like domain.
EMBO J. 30, 2853–2867 CrossRef PubMed
24 Whitby, F. G., Xia, G., Pickart, C. M. and Hill, C. P. (1998) Crystal structure of the human
ubiquitin-like protein NEDD8 and interactions with ubiquitin pathway enzymes. J. Biol.
Chem. 273, 34983–34991 CrossRef PubMed
25 Bain, J., Plater, L., Elliott, M., Shpiro, N., Hastie, C. J., McLauchlan, H., Klevernic, I.,
Arthur, J. S., Alessi, D. R. and Cohen, P. (2007) The selectivity of protein kinase
inhibitors: a further update. Biochem. J. 408, 297–315 CrossRef PubMed
26 Campbell, D. G. and Morrice, N. A. (2002) Identification of protein phosphorylation sites
by a combination of mass spectrometry and solid phase Edman sequencing. J. Biomol.
Tech. 13, 119–130 PubMed
27 Kazlauskaite, A., Kelly, V., Johnson, C., Baillie, C., Hastie, C. J., Peggie, M., Macartney, T.,
Woodroof, H. I., Alessi, D. R., Pedrioli, P. G. and Muqit, M. M. (2014) Phosphorylation of
Parkin at Serine65 is essential for activation: elaboration of a Miro1 substrate-based
assay of Parkin E3 ligase activity. Open Biol. 4, 130213 CrossRef PubMed
28 Burchell, L., Chaugule, V. K. and Walden, H. (2012) Small, N-terminal tags activate parkin
e3 ubiquitin ligase activity by disrupting its autoinhibited conformation. PLoS ONE 7,
e34748 CrossRef PubMed
29 Tomoo, K., Mukai, Y., In, Y., Miyagawa, H., Kitamura, K., Yamano, A., Shindo, H. and
Ishida, T. (2008) Crystal structure and molecular dynamics simulation of ubiquitin-like
domain of murine parkin. Biochim. Biophys. Acta 1784, 1059–1067 CrossRef PubMed
30 Tashiro, M., Okubo, S., Shimotakahara, S., Hatanaka, H., Yasuda, H., Kainosho, M.,
Yokoyama, S. and Shindo, H. (2003) NMR structure of ubiquitin-like domain in PARKIN:
gene product of familial Parkinson’s disease. J. Biomol. NMR 25,
153–156 CrossRef PubMed
31 Sakata, E., Yamaguchi, Y., Kurimoto, E., Kikuchi, J., Yokoyama, S., Yamada, S., Kawahara,
H., Yokosawa, H., Hattori, N., Mizuno, Y. et al. (2003) Parkin binds the Rpn10 subunit of
26S proteasomes through its ubiquitin-like domain. EMBO Rep. 4,
301–306 CrossRef PubMed
32 Trempe, J. F., Chen, C. X., Grenier, K., Camacho, E. M., Kozlov, G., McPherson, P. S.,
Gehring, K. and Fon, E. A. (2009) SH3 domains from a subset of BAR proteins define a
Ubl-binding domain and implicate parkin in synaptic ubiquitination. Mol. Cell 36,
1034–1047 CrossRef PubMed
33 Pearce, L. R., Komander, D. and Alessi, D. R. (2010) The nuts and bolts of AGC protein
kinases. Nat. Rev. Mol. Cell Biol. 11, 9–22 CrossRef PubMed
34 Dou, H., Buetow, L., Sibbet, G. J., Cameron, K. and Huang, D. T. (2013) Essentiality of a
non-RING element in priming donor ubiquitin for catalysis by a monomeric E3. Nat.
Struct. Mol. Biol. 20, 982–986 CrossRef PubMed
35 Clark, K., Nanda, S. and Cohen, P. (2013) Molecular control of the NEMO family of
ubiquitin-binding proteins. Nat. Rev. Mol. Cell Biol. 14, 673–685 CrossRef PubMed
36 Swaminathan, G. and Tsygankov, A. Y. (2006) The Cbl family proteins: ring leaders in
regulation of cell signaling. J. Cell. Physiol. 209, 21–43 CrossRef PubMed
37 Lee, H. J., Na, K., Kwon, M. S., Kim, H., Kim, K. S. and Paik, Y. K. (2009) Quantitative
analysis of phosphopeptides in search of the disease biomarker from the hepatocellular
carcinoma specimen. Proteomics 9, 3395–3408 CrossRef PubMed
38 Malik, R., Lenobel, R., Santamaria, A., Ries, A., Nigg, E. A. and Korner, R. (2009)
Quantitative analysis of the human spindle phosphoproteome at distinct mitotic stages. J.
Proteome Res. 8, 4553–4563 CrossRef PubMed
39 Bennetzen, M. V., Larsen, D. H., Bunkenborg, J., Bartek, J., Lukas, J. and Andersen, J. S.
(2010) Site-specific phosphorylation dynamics of the nuclear proteome during the DNA
damage response. Mol. Cell. Proteomics 9, 1314–1323 CrossRef PubMed
40 Gu, T. L., Deng, X., Huang, F., Tucker, M., Crosby, K., Rimkunas, V., Wang, Y., Deng, G.,
Zhu, L., Tan, Z. et al. (2011) Survey of tyrosine kinase signaling reveals ROS kinase
fusions in human cholangiocarcinoma. PLoS ONE 6, e15640 CrossRef PubMed
41 Bedford, L., Lowe, J., Dick, L. R., Mayer, R. J. and Brownell, J. E. (2011) Ubiquitin-like
protein conjugation and the ubiquitin-proteasome system as drug targets. Nat. Rev. Drug
Discovery 10, 29–46 CrossRef
Received 12 March 2014/24 March 2014; accepted 25 March 2014
Published as BJ Immediate Publication 25 March 2014, doi:10.1042/BJ20140334
c© 2014 The Author(s) The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Licence (CC-BY) (http://creativecommons.org/licenses/by/3.0/) which
permits unrestricted use, distribution and reproduction in any medium, provided the original work is properly cited.
Biochem. J. (2014) 460, 127–139 (Printed in Great Britain) doi:10.1042/BJ20140334
SUPPLEMENTARY ONLINE DATA
Parkin is activated by PINK1-dependent phosphorylation of ubiquitin at Ser65
Agne KAZLAUSKAITE*1, Chandana KONDAPALLI*, Robert GOURLAY*, David G. CAMPBELL*, Maria Stella RITORTO*,
Kay HOFMANN†, Dario R. ALESSI*, Axel KNEBEL*, Matthias TROST* and Miratul M. K. MUQIT*‡1
*MRC Protein Phosphorylation and Ubiquitylation Unit, University of Dundee, Dundee, Scotland, U.K.
†Institute for Genetics, University of Cologne, Cologne, Germany
‡College of Medicine, Dentistry & Nursing, University of Dundee, Dundee, Scotland, U.K.
Figure S1 Reproducible phosphorylation of ubiquitin upon PINK1 stimulation by CCCP in vivo
Flp-In T-Rex HEK-293 cells stably expressing FLAG-empty, wild-type PINK1–FLAG or kinase-inactive PINK1–FLAG were grown in light, heavy and medium SILAC media respectively. Cells in
each condition were stimulated with 10μM CCCP for 3 h. Subsequently, membrane fractions were enriched by ultracentrifugation and solubilized in 1 % RapiGest. Lysates from each of the three
conditions were mixed at 1:1:1 and digested with trypsin before phosphopeptide enrichment by HILIC and TiO2, and analysis by MS. Data analysis was performed using MaxQuant. (A–D) Extracted
ion chromatograms representing the ubiquitin Ser65 phosphopeptide TLSDYNIQKEpSTLHLVLR in the three SILAC-labelled conditions over all four biological replicates. There is a ∼14-fold increase
in abundance in cells transfected in the wild-type PINK1–FLAG compared with the kinase-inactive PINK1–FLAG.
1 Correspondence may be addressed to either of these authors (a.kazlauskaite@dundee.ac.uk or m.muqit@dundee.ac.uk).
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Figure S2 MS/MS fragmentation spectra of the phosphorylated ubiquitin
peptide TLSDYNIQKEpSTLHLVLR
(A) MS/MS spectrum of the heavy (R10K8)-labelled peptide TLSDYNIQKEpSTLHLVLR identified
in wild-type PINK1–FLAG-transfected cells. (B) Virtually identical MS/MS spectrum of
TLSDYNIQKEpSTLHLVLR from a digest of ubiquitin in vitro phosphorylated by TcPINK1. Note
that the doubly charged ion [1105.5650]2 + of the same peptide was also positively identified
in both experiments with Andromeda and Mascot Scores of 202 and 54 respectively.
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